Karbinal Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522191 AYTU Modified release formulations containing drug—ion exchange resin complexes
Jun, 2027

(3 years from now)

US8062667 AYTU Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(5 years from now)

Karbinal Er is owned by Aytu.

Karbinal Er contains Carbinoxamine Maleate.

Karbinal Er has a total of 2 drug patents out of which 0 drug patents have expired.

Karbinal Er was authorised for market use on 28 March, 2013.

Karbinal Er is available in suspension, extended release;oral dosage forms.

The generics of Karbinal Er are possible to be released after 29 March, 2029.

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Market Authorisation Date: 28 March, 2013

Treatment: NA


More Information on Dosage

KARBINAL ER family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic